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A B S T R A C T
Background
Vitamin E supplementation may help reduce the risk of pregnancy complications involving oxidative stress, such as pre-eclampsia.
There is a need to evaluate the efficacy and safety of vitamin E supplementation in pregnancy.
Objectives
To assess the effects of vitamin E supplementation, alone or in combination with other separate supplements, on pregnancy outcomes,
adverse events, side-effects and use of health services.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (23 June 2004), the Cochrane Central Register of
Controlled Trials (The Cochrane Library, Issue 2, 2004), MEDLINE (1966 to May 2004), Current Contents (1998 to May 2004) and
EMBASE (1980 to May 2004). We updated the search of the Cochrane Pregnancy and Childbirth Group’s Trials Register on 7 May
2010 and added the results to the awaiting classification section.
Selection criteria
All randomised or quasi-randomised controlled trials evaluating vitamin E supplementation in pregnant women. We excluded inter-
ventions using a multivitamin supplement that contained vitamin E.
Data collection and analysis
Two authors independently assessed trials for inclusion, extracted data and assessed trial quality.
Main results
Four trials, involving 566 women either at high risk of pre-eclampsia or with established pre-eclampsia, were eligible for this review.
All trials assessed vitamin E in combination with other supplements and two trials were published in abstract form only. No difference
was found between women supplemented with vitamin E in combination with other supplements during pregnancy compared with
placebo for the risk of stillbirth (relative risk (RR) was 0.77, 95% confidence intervals (CI) 0.35 to 1.71, two trials, 339 women),
neonatal death (RR 5.00, 95% CI 0.64 to 39.06, one trial, 40 women), perinatal death (RR 1.29, 95% CI 0.67 to 2.48, one trial,
56 women), preterm birth (RR 1.29, 95% CI 0.78 to 2.15, two trials, 383 women), intrauterine growth restriction (RR 0.72, 95%
CI 0.49 to 1.04, two trials, 383 women) or birthweight (weighted mean difference -139.00 g, 95% CI -517.68 to 239.68, one trial,
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100 women), using fixed-effect models. Substantial heterogeneity was found for pre-eclampsia. Women supplemented with vitamin E
in combination with other supplements compared with placebo were at decreased risk of developing clinical pre-eclampsia (RR 0.44,
95% CI 0.27 to 0.71, three trials, 510 women) using fixed-effect models; however, this difference could not be demonstrated when
using random-effects models (RR 0.44, 95% CI 0.16 to 1.22, three trials, 510 women). There were no differences between women
supplemented with vitamin E compared with placebo for any of the secondary outcomes.
Authors’ conclusions
The data are too few to say if vitamin E supplementation either alone or in combination with other supplements is beneficial during
pregnancy.
[Note: The 24 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]
P L A I N L A N G U A G E S U M M A R Y
Vitamin E supplementation in pregnancy
Not enough evidence to determine if giving women vitamin E during pregnancy helps prevent their babies dying, being born small or
too soon.
For pregnant women, insufficient dietary vitamin E (found in vegetable oils, nuts, cereals and some leafy green vegetables) may lead to
complications like pre-eclampsia and the baby being born small. The review of trials found no studies on vitamin E supplementation
alone, but studies included vitamin C, and additional supplements or drugs. There was not enough evidence to say if vitamin E in
combination with other supplements during pregnancy improved outcomes for women and babies.
B A C K G R O U N D
Vitamin E is the generic name given to eight lipid soluble and
plant-derived compounds, four are referred to as tocopherols (al-
pha, beta, gamma, delta) and four are known as tocotrienols (al-
pha, beta, gamma, delta) (Roberts 1990). Natural source alpha-
tocopherol is the most biologically active form of vitamin E, and
consequently vitamin E activity is expressed in terms of alpha-to-
copherol equivalents (mg alpha-TE). In foods, tocopherol is found
highest in wheatgerm oil and other vegetable oils, nuts, some ce-
reals and some leafy green vegetables (NHMRC 1991). With a
standard healthy diet, intake of vitamin E would be up to 30 mg
alpha-TE per day unless wheatgerm oil is a major dietary con-
stituent (NHMRC 1991). Synthetic forms of vitamin E are also
available and commonly used in vitamin preparations; however,
these forms have less biological activity than their naturally occur-
ring counterparts (IOM 2000).
Vitamin E deficiency is rarely seen in healthy adults and has pri-
marily been characterised in preterm infants, low birthweight in-
fants and those with fat malabsorption disorders. Reported symp-
toms of deficiency include haemolytic anaemia, reticulocytosis,
hyperbilirubinaemia, low haemoglobin levels (Gross 1982) and
peripheral neuropathy (Roberts 1990). Vitamin E deficiency is
exacerbated in the presence of iron overload and a high dietary
intake of polyunsaturated fatty acids (PUFAs), which is of par-
ticular relevance for preterm infants fed formula containing high
levels of iron and PUFAs (Roberts 1990). Establishing a recom-
mended dietary intake (RDI) of vitamin E has been impeded by
the low observance of overt vitamin E deficiency; however, current
RDI range from 7 mg to 10 mg alpha-TE (Roberts 1990). Dur-
ing pregnancy, losses of vitamin E to the fetus are thought to be
minimal and thus the RDI during pregnancy is often unchanged
(NHMRC 1991).
Vitamin E functions as an antioxidant in the lipid phase, protect-
ing phospholipid fatty acids from oxidation by harmful free rad-
icals (reactive oxygen molecules) and thus stabilising cell mem-
branes. As an antioxidant, vitamin E helps to prevent oxidative
stress, which is characterised by an excess of free radicals coupled
with decreased antioxidants available to quench these free radicals.
Vitamin E interacts synergistically with vitamin C, a water soluble
antioxidant, where vitamin C helps to convert oxidised vitamin
E back into a useful form (Packer 1979). This relationship may
account for the limited observation of overt vitamin E deficiency
in humans, as vitamin Cmay aid in recycling vitamin E stores. Vi-
tamin E and vitamin C supplements are often given concurrently
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to utilise this relationship and to promote antioxidant defences in
both the aqueous and lipid phase. Little is known about other po-
tential functions of vitamin E as research to date has focussed on
its antioxidant properties. Doses of vitamin E required to have an
antioxidant effect have been reported at least to 400 international
units (approximately 268 mg alpha-TE) (Devaraj 1997).
Oxidative stress has been linked to the development of adult dis-
eases including cardiovascular disease, cancer, chronic inflamma-
tion and neurologic disorders, resulting in many large multicentre
clinical trials of vitamin E supplementation. The results of these
large trials of vitamin E supplementation have been inconclusive,
and benefits remain to be consistently reported (Brigelius-Flohe
2002). During pregnancy, oxidative stress has been implicated
in the development of pre-eclampsia (Roberts 1990), and pro-
posed in the disease processes of intrauterine growth restric-
tion (Kingdom 2000) and prelabour rupture of membranes both
preterm and at term (Woods 2001). Oxidative stress has also
been implicated in many of the disorders common to preterm
infants including chronic lung disease, intraventricular haem-
orrhage, periventricular leukomalacia, retinopathy of prematu-
rity, necrotising enterocolitis and bronchopulmonary dysplasia
(Saugstad 1988; Saugstad 2001). Preventing complications in
pregnancy like pre-eclampsia, growth restriction, preterm prema-
ture rupture ofmembranes and serious neonatalmorbiditieswould
represent significant cost savings in hospital and intensive care
unit admissions and the use of other healthcare resources. Other
Cochrane reviews are assessing ’Antioxidants for preventing pre-
eclampsia’ (Rumbold 2005a) and ’Vitamin C supplementation in
pregnancy’ (Rumbold 2005b).
Vitamin E appears to have low toxicity in humans. However there
is limited evidence on the safety of using vitamin E in pregnancy.
Despite the lack of evidence on safety, the United States Institute
of Medicine Food and Nutrition Board has set an upper tolerable
limit of vitamin E ingestion in pregnancy at 1000 mg per day
(IOM 2000), indicating the highest level of intake that is likely to
pose no risk of adverse health effects to almost all women. In non-
pregnant adults controlled clinical trials of vitamin E supplemen-
tation in a variety of doses have failed to demonstrate any consis-
tent side-effects (Bendich 1993). Observational studies, however,
have reported adverse effects including fatigue, weakness, creatin-
uria, dermatitis, reduced thyroid function, increased urinary an-
drogen excretion, reduced leukocyte action and altered coagula-
tion factors resulting in increased bleeding in vitamin K deficient
individuals (Bendich 1993; Roberts 1990). The mechanisms lead-
ing to altered coagulation factors are unclear; however, vitamin E
has been reported to potentiate the effect of anticoagulant ther-
apy, such as warfarin. Newborn infants have a relative vitamin
K deficiency at birth, hence vitamin E supplementation during
pregnancy may influence the risk of vitamin K deficiency bleeding
or haemorrhagic disease of the newborn unfavourably if vitamin
K is not given at birth. In controlled trials of vitamin E supple-
mentation in preterm infants for the treatment of retinopathy of
prematurity, vitamin E supplementation has been associated with
an increased risk of bacterial sepsis and necrotising enterocolitis
(Johnson 1985). Given the lipid soluble nature of vitamin E, sup-
plementation may result in increased storage of the vitamin in or-
gans such as the liver, muscle and adipose tissue when used in high
doses. The need to demonstrate the efficacy and safety of using
vitamin E in pregnancy is particularly important when vitamin E
is given in high doses.
The aims of this review are (i) to identify all published, unpub-
lished randomised and quasi-randomised controlled trials investi-
gating vitamin E supplementation in pregnancy and (ii) to inves-
tigate the benefits and hazards of vitamin E supplementation in
pregnancy.
O B J E C T I V E S
To assess, using the best available evidence, the effects of vitamin
E supplementation, alone or in combination with other separate
supplements, on pregnancy outcomes, adverse events, side-effects
and use of health services.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised or quasi-randomised controlled trials evaluating
the effect of vitamin E supplementation in pregnant women.
Types of participants
Pregnant women receiving vitamin E supplementation or control,
living in areas where there is either inadequate dietary intake of
vitamin E or where there is presumed adequate intake.
Women were classified into subgroups where possible, based on:
(a) the dosage of the vitamin E supplement (above or equal to/
below the recommended dietary intake of 7 mg alpha-TE);
(b) the gestation at trial entry (trial entry less than 20 weeks or
greater than or equal to 20 weeks);
(c) whether women have low or adequate dietary vitamin E intake
prior to trial entry (low intake defined as intake less than the
recommended dietary intake in that setting as measured by dietary
questionnaire);
(d) the use of vitamin E in combination with other dietary sup-
plements;
(e) women’s risk status for adverse pregnancy outcomes (as defined
by the trial authors).
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Types of interventions
Vitamin E supplementation, alone or in combination with other
separate supplements compared with placebo, no placebo or
other supplements. Interventions using a multivitamin supple-
ment (more than two vitamins or minerals combined in the one
tablet preparation) that contained vitamin E were excluded.
Types of outcome measures
Primary outcomes
1. Stillbirth, neonatal death, perinatal death or infant death;
2. maternal and infant haematological measures: haemolytic
anaemia, reticulocytosis, hyperbilirubinaemia and haemoglobin
concentrations;
3. preterm birth (defined as less than 37 weeks’ gestation);
4. development of clinical pre-eclampsia;
5. intrauterine growth restriction (defined as birthweight less
than third centile or the most extreme centile reported);
6. birthweight;
7. prelabour rupture of fetal membranes, preterm and at term.
Secondary outcomes
For the mother: death up to six weeks postpartum, elective deliv-
ery (induction of labour or elective caesarean section), caesarean
section (emergency plus elective), bleeding episodes (such as pla-
cental abruption, antepartum haemorrhage, postpartum haemor-
rhage, complications of epidural anaesthesia, need for transfusion),
measures of serious maternal morbidity (such as eclampsia, liver
failure, renal failure, disseminated intravascular coagulation, pul-
monary oedema), peripheral neuropathy andmaternal satisfaction
with care.
For the child: gestational age at birth, congenital malformations,
Apgar score less than seven at five minutes, vitamin K deficiency
bleeding or haemorrhagic disease of the newborn, respiratory dis-
tress syndrome, chronic lungdisease, periventricular haemorrhage,
periventricular leukomalacia, bacterial sepsis, necrotising entero-
colitis, retinopathy of prematurity, bronchopulmonary dysplasia,
peripheral neuropathy, disability at childhood follow up (such as
cerebral palsy, intellectual disability, hearing disability and visual
impairment) and poor childhood growth.
Adverse events related to vitamin E supplementation sufficient to
stop supplementation.
Side-effects of vitamin E supplementation such as fatigue, weak-
ness, altered coagulation times, immunosuppression, creatinuria,
dermatitis, altered thyroid function and increased urinary andro-
gen excretion.
Use of health service resources
For the woman: antenatal hospital admission, visits to day care
units, use of intensive care, ventilation and dialysis.
For the infant: admission to special care/intensive care nursery,
duration of mechanical ventilation, length of stay in hospital, as
well as development and special needs after discharge.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group trials
register by contacting the Trials Search Co-ordinator (23 June
2004). We updated this on 7 May 2010 and added the results to
Studies awaiting classification.
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can
be found in the ‘Specialized Register’ section within the edito-
rial information about the Cochrane Pregnancy and Childbirth
Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
In addition, we searched the Cochrane Central Register of Con-
trolled Trials (The Cochrane Library 2004, Issue 2), MEDLINE
(1966 to May 2004), Current Contents (1998 to May 2004) and
EMBASE (1980 to May 2004) for potentially eligible studies, us-
ing the search strategies detailed in Appendix 1.
We did not apply any language restrictions.
Data collection and analysis
Two authors assessed potentially eligible trials found after the lit-
erature search for their suitability for inclusion in the review. De-
cisions regarding inclusion were made separately and results com-
pared. We resolved any disagreement through discussion. Two au-
thors extracted data using an agreed format, and again we resolved
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discrepancies through discussion. We entered data separately and
double checked them.
We assessed the validity of each included trial according to the
criteria outlined in the Cochrane Reviewers’ Handbook (Clarke
2000). We assessed trials with a grade allocated to each trial on
the basis of allocation concealment: A (adequate), B (unclear) or
C (clearly inadequate). Where the method of allocation conceal-
ment was unclear, we made attempts to contact authors to provide
further details.
We assessed blinding, completeness of followup and use of placebo
for each outcome using the following criteria.
For blinding of assessment of outcome
A. Double blind, neither investigator, the outcome assessor nor
participant knew or were likely to guess the allocated treatment;
B. single blind, either the investigator or the participant knew the
allocation; or, the trial is described as double blind, but side-effects
of one or other treatment mean that it is likely that for a significant
proportion (at least 20%) of participants the allocation could be
correctly identified;
C. no blinding, where the investigator, outcome assessor and par-
ticipant knew (or were likely to guess) the allocated treatment;
D. unclear.
For completeness of follow up
A. Less than 3% of participants excluded;
B. 3% to 9.9% of participants excluded;
C. 10% to 19.9% of participants excluded;
D. excluded: greater thanor equal to 20%of participants excluded.
For use of placebo control
A. Placebo controlled;
B. unclear whether placebo controlled;
C. no placebo control.
We carried out statistical analyses using the Review Manager soft-
ware (RevMan 2004) with results presented as summary relative
risk. We applied tests of heterogeneity between trials to assess the
significance of any differences between trials (I2 greater than or
equal to 50%) and explored possible causes of heterogeneity. We
calculated summary relative risks using a fixed-effectmodel. If het-
erogeneity was detected, we performed subgroup analyses for the
main outcomes by vitamin E dosage, gestation at trial entry, prior
dietary intake of vitamin E, use of vitamin E in combination with
other supplements, and women’s risk status of adverse pregnancy
outcomes as defined by the authors. Heterogeneity that was not
explained by subgroup analyses was modelled using random-ef-
fects analysis.
We included all included trials in the initial analyses and carried
out sensitivity analyses to explore the effect of trial quality. This in-
volved analysis based on an A, B or C rating of allocation conceal-
ment, blinding of assessment of outcome, completeness of follow
up and placebo control. We compared the results of high-quality
studies with those of poorer quality studies, where studies rated A
for all quality criteria were compared with those rated B or C.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
See tables ’Characteristics of included studies’ and ’Characteristics
of excluded studies’ for details of individual studies.
We identified four trials involving 566 women as eligible for in-
clusion in the review. Of these, three trials assessed vitamin E sup-
plementation for the prevention of pre-eclampsia (Beazley 2002;
Chappell 1999; Rivas 2000). One trial assessed vitamin E supple-
mentation for the prevention of serious maternal complications
and iatrogenic preterm birth in women with established early on-
set pre-eclampsia (Gulmezoglu 1997).
Six studies were excluded, either because no clinically meaningful
data were reported in a format suitable for inclusion (Anthony
1996; Pressman 2003; Sawhney 2000) or the studies were non-
randomised (Bolisetty 2002; Lietz 2001; Moldenhauer 2002).
(Twenty-three reports from an updated search in May 2010 have
been added to Studies awaiting classification.)
Participants
Three trials recruitedwomenwhowere at “high risk of pre-eclamp-
sia” (Beazley 2002; Chappell 1999; Rivas 2000). The criteria for
women being at high risk varied between trials, and included: pre-
vious pre-eclampsia, chronic hypertension, insulin-requiring di-
abetes mellitus or multiple gestation (Beazley 2002); abnormal
doppler waveform in either uterine artery at 18 to 22 weeks’ ges-
tation or a history in the preceding pregnancy of pre-eclamp-
sia necessitating delivery before 37 weeks’ gestation, eclampsia or
the syndrome of haemolysis, elevated liver enzymes, low platelets
(Chappell 1999); or nulliparity, previous pre-eclampsia, obesity,
hypertension, less than 20 years old, diabetes, nephropathy, mean
arterial presion above of 85 mmHg, positive roll-over test, black
race, family history of hypertension or pre-eclampsia, twin preg-
nancy and poor socioeconomic conditions (Rivas 2000). The
fourth trial involved women with established severe early onset
pre-eclampsia (Gulmezoglu 1997). The timing of commencement
of supplementation differed widely, one trial enrolled women be-
tween 14 and 20 weeks’ gestation (Beazley 2002), while others
enrolled women between 16 and 22 weeks’ gestation (Chappell
1999), 24 to 32 weeks’ gestation (Gulmezoglu 1997) or any
women below 29 weeks’ gestation (Rivas 2000).
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Interventions
All of the four trials gave women supplements with vitamin E
in addition to vitamin C. Two trials supplemented women with
additional supplements, either allopurinol (Gulmezoglu 1997) or
aspirin and fish oil (Rivas 2000). Three trials used the same dose
of daily 400 international units (IU) vitamin E (Beazley 2002;
Chappell 1999; Rivas 2000) and the fourth trial gave women daily
800 IU vitamin E (Gulmezoglu 1997).
Outcomes
Primary outcomes
Few trials reported many of the primary or secondary out-
comes. Stillbirth was reported by two trials (Chappell 1999;
Gulmezoglu 1997), neonatal death and perinatal death by one
trial (Gulmezoglu 1997) and no trials reported any data for infant
deaths. No trials reported any data on maternal and infant haema-
tological measures including haemolytic anaemia, reticulocyto-
sis, hyperbilirubinaemia and haemoglobin concentrations. For the
other primary outcomes, two trials reported pretermbirth (Beazley
2002; Chappell 1999); three trials reported pre-eclampsia (Beazley
2002; Chappell 1999; Rivas 2000); two trials reported intrauter-
ine growth restriction as birthweight less than the 10th centile for
gestational age (Beazley 2002; Chappell 1999); one trial reported
mean birthweight in a format suitable for inclusion in the review
(Beazley 2002); and two trials reported median birthweight and
range or interquartile range (Chappell 1999; Gulmezoglu 1997).
No trials reported prelabour rupture of membranes either preterm
or at term.
Secondary outcomes
One trial reportedmaternal death (Gulmezoglu 1997), one trial re-
ported prelabour caesarean section (Gulmezoglu 1997), two trials
reported placental abruption (Chappell 1999; Gulmezoglu 1997)
and one trial reported measures of serious maternal morbidity in-
cluding eclampsia, renal failure, disseminated intravascular coag-
ulation and pulmonary oedema (Gulmezoglu 1997). One trial re-
ported gestational age at birth (Beazley 2002) and one trial re-
ported Apgar score less than seven at five minutes (Gulmezoglu
1997).
No trials reported maternal or infant peripheral neuropathy, ma-
ternal satisfaction with care, congenital malformations, vitamin K
deficiency bleeding or haemorrhagic disease of the newborn, res-
piratory distress syndrome, chronic lung disease, periventricular
haemorrhage or leukomalacia, bacterial sepsis, necrotising entero-
colitis, retinopathy of prematurity, bronchopulmonary dysplasia,
disability at childhood follow up, poor childhood growth or any
adverse events related to vitamin E supplementation.
One trial reported side-effects of vitamin E supplementation,
neonatal admission to the intensive care unit, and the need for
mechanical ventilation (Gulmezoglu 1997).No trials reported any
data for maternal use of health resources.
Risk of bias in included studies
Allocation concealment
Formal randomisation was reported in two trials by use of third
party randomisation (Chappell 1999; Gulmezoglu 1997). For the
remaining two trials (Beazley 2002; Rivas 2000), the degree of
concealment was unclear; both were reported as abstracts and gave
no information about methods of randomisation.
Blinding
Two trials explicitly stated that women, caregivers and re-
searchers were blinded to treatment allocations (Chappell 1999;
Gulmezoglu 1997). One trial stated “double-blind” in the text
(Beazley 2002) while the other trial used the term “triple-blind”
in the text (Rivas 2000).
Completeness of follow up
Three trials either reported outcomes for all randomised women
according to treatment allocation (Chappell 1999) or did not state
any losses to follow up (Gulmezoglu 1997; Rivas 2000). One trial
(Beazley 2002) reported nine women (eight per cent) were lost to
follow up.
Use of placebo
All four trials used a placebo. The content of the placebo used
was explicitly stated for one trial (microcrystalline cellulose and
soya bean oil) (Chappell 1999), however no details of the placebo
preparation were disclosed for the remaining three trials (Beazley
2002; Gulmezoglu 1997; Rivas 2000).
Effects of interventions
Four trials, involving 566 women, are included.
Primary outcomes
No difference was found between women supplemented with vi-
tamin E in combination with other supplements compared with
placebo for the risk of stillbirth (relative risk (RR) 0.77, 95%
confidence intervals (CI) 0.35 to 1.71, two trials, 339 women
(Chappell 1999; Gulmezoglu 1997)), neonatal death (RR 5.00,
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95% CI 0.64 to 39.06, one trial, 40 women (Gulmezoglu 1997))
or perinatal death (RR 1.29, 95% CI 0.67 to 2.48, one trial, 56
women (Gulmezoglu 1997)), using fixed-effect models. No trials
reported the outcomes infant death, haemolytic anaemia, reticu-
locytosis, hyperbilirubinaemia or maternal or infant haemoglobin
concentrations.
No difference was demonstrated in the risk of preterm birth be-
tween women supplemented with vitamin E in combination with
other supplements comparedwith placebo (RR1.29, 95%CI 0.78
to 2.15, two trials, 383 women (Beazley 2002; Chappell 1999)).
Women supplemented with vitamin E in combination with other
supplements compared with placebo were at decreased risk of de-
veloping clinical pre-eclampsia (RR 0.44, 95% CI 0.27 to 0.71,
three trials, 510 women (Beazley 2002; Chappell 1999; Rivas
2000)), using a fixed-effect model. However, substantial hetero-
geneity was found for pre-eclampsia. When using a random-ef-
fects model, a difference in the risk of pre-eclampsia between treat-
ment groups could not be demonstrated (RR 0.44, 95% CI 0.16
to 1.22, three trials, 510 women (Beazley 2002; Chappell 1999;
Rivas 2000)).
No difference was found for the risk of intrauterine growth re-
striction (RR 0.72, 95% CI 0.49 to 1.04, two trials, 383 women
(Beazley 2002; Chappell 1999)) or birthweight (weighted mean
difference (WMD) -139.00 g, 95% CI -517.68 to 239.68, one
trial, 100 women (Beazley 2002)), between women supplemented
with vitamin E in combination with other supplements compared
with placebo. No trials provided data on prelabour rupture of
membranes either preterm or at term.
Secondary outcomes
One trial (Gulmezoglu 1997) reported that there were no mater-
nal deaths in either treatment arm. There was no difference be-
tween women supplemented with vitamin E in combination with
other supplements compared with placebo for prelabour caesarean
section (RR 1.51, 95% CI 0.86 to 2.63, one trial, 55 women
(Gulmezoglu 1997)), placental abruption (RR 0.35, 95% CI 0.10
to 1.23, two trials, 339 women (Chappell 1999; Gulmezoglu
1997)), eclampsia (RR 1.07, 95% CI 0.07 to 16.33, one trial, 56
women (Gulmezoglu 1997)), renal failure (RR 0.36, 95%CI 0.02
to 8.41, one trial, 56 women (Gulmezoglu 1997)), disseminated
intravascular coagulation (RR 0.36, 95% CI 0.02 to 8.41, one
trial, 56 women (Gulmezoglu 1997)), pulmonary oedema (RR
0.54, 95% CI 0.05 to 5.59, one trial, 56 women (Gulmezoglu
1997)), gestational age at birth (WMD -0.40 weeks, 95% CI -
1.87 to 1.07, one trial, 100 women (Beazley 2002)) or Apgar score
less than seven at five minutes (RR 0.63, 95% CI 0.21 to 1.90,
one trial, 39 women (Gulmezoglu 1997)).
No trials reported maternal or infant peripheral neuropathy, ma-
ternal satisfaction with care, congenital malformations, vitamin K
deficiency bleeding or haemorrhagic disease of the newborn, res-
piratory distress syndrome, chronic lung disease, periventricular
haemorrhage or leukomalacia, bacterial sepsis, necrotising entero-
colitis, retinopathy of prematurity, bronchopulmonary dysplasia,
disability at childhood follow up, poor childhood growth or any
adverse events related to vitamin E supplementation.
One trial reported side-effects of supplementation with vitamin
E in combination with other supplements. However, there was
no difference in the risk of developing acne (RR 3.21, 95% CI
0.14 to 75.68, one trial, 56 women (Gulmezoglu 1997)), tran-
sient weakness (RR 5.36, 95% CI 0.27 to 106.78, one trial, 56
women (Gulmezoglu 1997)) or skin rash (RR 3.21, 95% CI 0.14
to 75.68, one trial, 56 women (Gulmezoglu 1997)) between treat-
ment groups. For women supplemented with vitamin E in com-
bination with other supplements compared with placebo, there
was no difference in the number of infants admitted to the in-
tensive care unit (RR 0.83, 95% CI 0.30 to 2.29, one trial, 40
infants (Gulmezoglu 1997)) or requiring mechanical ventilation
(RR 0.33, 95%CI 0.08 to 1.46, one trial, 40 infants (Gulmezoglu
1997)). No data for maternal use of health resources were reported
by any of the trials.
Sensitivity analyses by trial quality
Assessments of the treatment effects were made for the pri-
mary outcomes based on trial quality. Two trials (Chappell 1999;
Gulmezoglu 1997) fulfilled the highest criteria for all of the quality
measures, that is they were rated ’A’ for allocation concealment,
had no losses to follow up, involved blinding of women, caregivers
and researchers and used placebo control. Two trials did not fulfil
the highest criteria for all of the quality measures (Beazley 2002;
Rivas 2000) and these trials were excluded from the analyses. For
the outcomes stillbirth, neonatal death and perinatal death, all
included trials were of high quality (Chappell 1999; Gulmezoglu
1997). There was no difference between women supplemented
with vitamin E compared with placebo for the risk of stillbirth
(RR 0.77, 95% CI 0.35 to 1.71, two trials, 339 women (Chappell
1999;Gulmezoglu 1997)), neonatal death (RR5.00, 95%CI 0.64
to 39.06, one trial, 40 women (Gulmezoglu 1997)) or perina-
tal death (RR 1.29, 95% CI 0.67 to 2.48, one trial, 56 women
(Gulmezoglu 1997)).
When trials not rated high qualitywere excluded from the analyses,
the risk of pretermbirth, pre-eclampsia and intrauterine growth re-
striction did not change; however, the confidence intervals around
the relative risks changed slightly. No difference was seen for the
risk of preterm birth between women supplemented with vitamin
E compared with placebo (RR 1.21, 95% CI 0.38 to 3.87, one
trial, 283 women (Chappell 1999)). For the outcome pre-eclamp-
sia, women supplemented with vitamin E compared with placebo
were at lower risk of pre-eclampsia (RR 0.46, 95% CI 0.24 to
0.91, one trial, 283 women (Chappell 1999)), using a random-
effects model. There was no difference in the risk of intrauterine
growth restriction for women supplemented with vitamin E com-
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pared with placebo (RR 0.74, 95% CI 0.50 to 1.08, one trial, 283
women (Chappell 1999)). The only trial reporting birthweight
was not rated high quality (Beazley 2002).
Subgroup analyses
Dosage of the vitamin E supplement (above or equal
to/below the recommended dietary intake of 7 mg alpha-TE)
All of the included studies supplemented women with vitamin E
in a dosage above the recommended dietary intake. Three trials
(Beazley 2002;Chappell 1999;Rivas 2000) supplementedwomen
with daily 400 international units (IU) vitamin E, and one trial
(Gulmezoglu 1997) supplemented women with daily 800 IU vi-
tamin E. Because of the lack of variation in dosage between trials,
subgroup analyses based on dosage were not performed.
Gestation at trial entry (less than 20 weeks or greater than
or equal to 20 weeks)
One trial (Beazley 2002) enrolledwomen from less thanor equal to
20 weeks’ gestation; one trial (Gulmezoglu 1997) enrolled women
after 20 weeks’ gestation; and the other trials (Chappell 1999;
Rivas 2000) enrolled women both before and after 20 weeks’ ges-
tation. There was no difference in the risk of stillbirth between
women supplemented with vitamin E compared with placebo af-
ter 20 weeks’ gestation (RR 0.84, 95% CI 0.36 to 1.93, one trial,
56 women (Gulmezoglu 1997)) or women supplemented both
before and after 20 weeks’ gestation (RR 0.50, 95% CI 0.05 to
5.49, one trial, 283 women (Chappell 1999)). There were no data
on stillbirth for the trial supplementing women before 20 weeks’
gestation. For preterm birth, there was no difference in the risk
of preterm birth between women supplemented with vitamin E
compared with placebo before to 20 weeks’ (RR 1.32, 95% CI
0.75 to 2.31, one trial, 100 women (Beazley 2002)) or for women
supplemented both before and after 20 weeks’ gestation (RR 1.21,
95% CI 0.38 to 3.87, one trial, 283 women (Chappell 1999)).
There were no data on preterm birth for the trial supplementing
women after 20 weeks’ gestation. There was no difference in the
risk of pre-eclampsia between women supplemented with vitamin
E compared with placebo before 20 weeks’ gestation (RR 0.92,
95% CI 0.40 to 2.13, one trial, 100 women (Beazley 2002)) or
for women supplemented both before and after 20 weeks’ ges-
tation (RR 0.23, 95% CI 0.04 to 1.46, two trials, 410 women
(Chappell 1999; Rivas 2000)), using random-effects models. Sim-
ilarly, there was no difference in the risk of intrauterine growth
restriction between women supplemented with vitamin E com-
pared with placebo before 20 weeks’ gestation (RR 0.46, 95% CI
0.09 to 2.41, one trial, 100 women (Beazley 2002)), or both be-
fore and after 20 weeks’ gestation (RR 0.74, 95% CI 0.50 to 1.08,
one trial, 283 women (Chappell 1999)). There were no data on
intrauterine growth restriction for the trial supplementing women
after 20 weeks’ gestation.
Low or adequate dietary vitamin E intake prior to trial entry
(low intake defined as intake less than the recommended
dietary intake in that setting as measured by dietary
questionnaire)
None of the trials reported any information on women’s dietary
intake of vitamin E prior to trial entry or during the trial. No
subanalyses could therefore be performed.
The use of vitamin E in combination with other dietary
supplements
None of the trials supplemented women with vitamin E alone.
All of the trials gave vitamin E in addition to vitamin C, and two
trials also supplemented women additionally with either allopuri-
nol (Gulmezoglu 1997) or aspirin and fish oil (Rivas 2000). Sub-
group analyses based on the use of vitamin E alone or with other
supplements were therefore not performed.
Women’s risk status for adverse pregnancy outcomes (as
defined by the authors)
Three trials supplemented women who were at high risk of pre-
eclampsia (Beazley 2002; Chappell 1999; Rivas 2000) and the
fourth trial supplemented women who had established early on-
set pre-eclampsia. Hence all women were classified as high risk
for adverse pregnancy outcomes, and subgroup analyses based on
women’s risk of adverse pregnancy outcomes were unable to be
performed.
D I S C U S S I O N
We cannot support routine vitamin E supplementation alone or
in combination with other supplements or drugs in pregnancy.
From the limited trials reviewed there are insufficient data for reli-
able conclusions about vitamin E supplementation in pregnancy.
The total number of women involved in the included trials was
small (566 in total), and two trials were of poor quality and pub-
lished in abstract form only. All of the women involved in the
trials were either at high risk of pre-eclampsia or had established
severe early onset pre-eclampsia. There was no information avail-
able to assess whether vitamin E supplementation may be useful
for all pregnant women. Similarly, all of the included trials assessed
vitamin E supplementation in combination with vitamin C and
other supplements including allopurinol or aspirin and fish oil.
There was no information available to assess whether vitamin E
supplementation alone may be beneficial for women, hence any
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treatment effects seen here may not be directly attributable to vita-
min E. For further information on vitamin C supplementation see
the Cochrane review ’Vitamin C supplementation in pregnancy’
(Rumbold 2005b). Trials of combined vitamin C and vitamin E
supplementation have been included in both reviews.
There was no information available to evaluate the impact of
vitamin E supplementation on important outcomes such as in-
fant death, measures of maternal and infant haematological status,
prelabour rupture of membranes (either preterm or term), serious
infant morbidities or maternal satisfaction with care. Similarly, for
the outcomes that were reported, not all trials reported all of these
outcomes, which creates the potential for bias and limits the reli-
ability of the results.
Substantial heterogeneity was detected for the outcome pre-
eclampsia. When poor quality trials were excluded from the anal-
yses, women supplemented with vitamin E had a reduced risk
of pre-eclampsia. Caution must be taken when interpreting this
finding as only one high-quality trial reported on pre-eclampsia,
and the number of women included in this trial was small. No
firm conclusions should be drawn from results of single trials with
small sample sizes. The role of vitamin E and other antioxidants
in the prevention of pre-eclampsia is being further explored in
the Cochrane Review ’Antioxidants for preventing pre-eclampsia’
(Rumbold 2005a). Further trials evaluating the role of vitamin
E supplementation in preventing pre-eclampsia are warranted for
women at high risk and low risk of pre-eclampsia.
One trial involving 56 women reported potential side-effects of
vitamin E supplementation, including acne, transient weakness
and skin rash. None of these outcomes were reported by any of
the women in the placebo group, however, the differences between
treatment groups for these outcomes were not statistically signifi-
cant. No other trials reported any potential side-effects or adverse
effects of vitamin E supplementation.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
From the limited trials reviewed, the data do not support routine
vitamin E supplementation either alone or in combination with
other supplements in pregnancy, for all women or women at high
risk of pregnancy complications. The data are too few to produce
any reliable conclusions about any benefits or harms of supple-
mentation.
Implications for research
There is currently no information available to assess any benefits
or harms of supplementing women during pregnancy with vita-
min E alone. The role of vitamin E supplementation either alone
or with other supplements such as vitamin C, aspirin and fish
oil in preventing pre-eclampsia needs to be further explored, for
women at high- and low-risk of pre-eclampsia. Future trials as-
sessing vitamin E supplementation should be of high quality and
large enough to assess pre-eclampsia and other serious maternal
and infant morbidities. Future trials should collect information on
maternal satisfaction with care, side-effects and adverse effects for
the mother and infant, including vitamin K deficiency bleeding in
the infant, and trials should involve long-term follow up to ensure
an accurate evaluation of the safety of vitamin E supplementation.
[Note: The 24 citations in the awaiting classification section of
the review may alter the conclusions of the review once assessed.]
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beazley 2002
Methods Treatment allocation: unclear, no methodological details given, women were “randomised”
Blinding of outcome assessment: “double blind” stated.
Documentation of exclusion: 9 (8%) women were lost to follow up
Use of placebo control: placebo control.
Participants 109 women were recruited into the study. Inclusion criteria: women at “high risk of pre-eclampsia”
including those with previous pre-eclampsia, chronic hypertension, pregestational diabetes and multiple
pregnancy. Nil exclusion criteria stated. Women were randomised at 14-20 weeks’ gestation to receive
either daily vitamin E and C (n = 54) or placebo (n = 55)
Interventions Women randomised to the treatment group received daily 400 IU vitamin E in addition to 1000 mg
vitamin C. No details on the content of the placebo were given
Outcomes 1. Pre-eclampsia (not defined).
2. GA at delivery (weeks).
3. Preterm birth (< 37 weeks’ gestation).
4. Birthweight.
5. Birthweight < 10 centile.
6. Total antioxidant status and 8-isoprostane.
Notes Dosage: daily 400 IU vitamin E, above RDI.
Gestational age at trial entry: <= 20 weeks’ gestation.
Dietary vitamin E intake before trial entry: unclear, no dietary information reported
Type of supplement: vitamin E given in addition to vitamin C
Women’s risk status: women were at high risk of pre-eclampsia
Intention to treat analyses: stated that analyses were intention to treat, however losses to follow up were
not included in the totals. Available case analysis
Sample size calculation: none reported.
Compliance: unclear, no details given.
Location: United States of America.
Timeframe: unclear.
Published in abstract format only.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Chappell 1999
Methods Treatment allocation: a computer-generated randomisation list using blocks of ten was given to the
hospital pharmacy departments. Researchers allocated the next available number to participants and
women collected the trial tablets from the pharmacy department
Blinding of outcome assessment: women, caregivers and researchers were blinded to the treatment allo-
cation until recruitment, data collection and laboratory analyses were complete
Documentation of exclusion: Pregnancy outcome data were reported according to treatment allocation
for all women randomised
Use of placebo control: placebo control.
Participants 283 women were recruited into the study. Inclusion criteria: abnormal Doppler waveform in either uterine
artery at 18-22 weeks’ gestation or a history in the preceding pregnancy of pre-eclampsia necessitating
delivery before 37 weeks’ gestation, eclampsia or the syndrome of HELLP.
Exclusion criteria: heparin or warfarin treatment, abnormal fetal-anomaly scan or multiple pregnancy.
Women were randomised at 18-22 weeks’ gestation; however, women with a previous history who were
identified at an earlier stage were randomised at 16 weeks’ gestation. Women with abnormal Doppler
waveform analysis returned for a second scan at 24 weeks’ gestation, those with a normal waveform at this
time stopped treatment and were withdrawn from the study. The remaining women who had persistently
abnormal waveforms and those with a previous history or pre-eclampsia remained in the study and were
seen every 4 weeks through the rest of pregnancy. 1512 women underwent Doppler screening, 273 women
had abnormal waveforms and, of these, 242 women consented to the study. An additional 41 women
who had a history of pre-eclampsia consented. 283 women were randomised to either the vitamin C and
E group (n = 141) or the placebo group (n = 142), 72 women had normal Doppler scans at 24 weeks’
gestation and 24 women did not return for a second scan and were withdrawn. A further 27 women
withdrew from the trial after 24 week’s gestation for various reasons. In total, 160 women completed the
trial protocol until delivery, 79 in the vitamin C and E group and 81 in the placebo group. Pregnancy
outcome data were presented for all women randomised (n = 283) as well as only for those women
completing the trial protocol (n = 160)
Interventions Women randomised to the vitamin E and C group received capsules containing 400 IU natural source
vitamin E daily and tablets containing 1000 mg vitamin C daily. Women randomised to the placebo
group received capsules containing soya bean oil and tablets containing microcrystalline cellulose that
were identical in appearance to the vitamin E capsules and vitamin C tablets.
After 24 weeks’ gestation women were seen every 4 weeks, and blood samples were taken at each visit
Outcomes 1. Ratio of PAI-1 to PAI-2.
2. Incidence of pre-eclampsia (defined according to the International Society for the Study ofHypertension
in Pregnancy guidelines).
3. Placental abruption.
4. Spontaneous preterm delivery (< 37 weeks’ gestation).
5. Intrauterine death.
6. Small-for-gestational-age infants (on or below the 10th centile).
7. Mean systolic and diastolic blood pressure before delivery.
8. Gestational age at delivery (median, IQR).
9. Birthweight (median, IQR).
10. Birthweight centile (median, IQR).
11. Mean plasma ascorbic acid and alpha-tocopherol concentrations during gestation.
12. Biochemical indices of oxidative stress and placental function
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Chappell 1999 (Continued)
Notes Dosage: 400 IU natural source vitamin E daily, above RDI.
GA at trial entry: between 16-22 weeks’ gestation.
Dietary vitamin E intake before trial entry: unknown, not assessed
Type of supplement: vitamin E given in addition to vitamin C
Women’s risk status: women were at “high risk for pre-eclampsia”
Intention to treat analyses: performed, pregnancy outcome data were available for all women randomised,
and results were presented according to initial treatment allocation
Sample size calculation: the study had 80% power to detect a 30% reduction in PAI-1
Compliance: not specifically reported. “Within the treated group, plasma ascorbic acid concentration
increased by 32% from baseline values and plasma alpha-tocopherol increased by 54%.”
Location: London, United Kingdom.
Timeframe: unclear.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Gulmezoglu 1997
Methods Treatment allocation: “The treatment packs were randomised by computer generated random numbers
in blocks of ten”. Randomisation was carried out by an independent researcher who was not involved in
the study, and medications were placed in consecutively numbered sealed opaque bags
Blinding of outcome assessment: women, caregivers and researchers were blinded to the treatment allo-
cation
Documentation of exclusion: no exclusions documented.
Use of placebo control: placebo control.
Participants 56 women were recruited into the study. Inclusion criteria: women who were admitted to the antenatal
wards with a diagnosis of severe pre-eclampsia, as defined by 2+ proteinuria on urine dipstix testing
(in at least two consecutive tests 4 to 6 hours apart), with a blood pressure of 160/110 mmHg, or 3+
proteinuria with blood pressure >= 150/100 mmHg; between 24 and 32 weeks’ gestation; with a single
live fetus; with no systemic disorder (such as diabetes or systemic lupus erythematosus) and no allergy to
study medications. Women were approached when they were eligible for conservative management, as
defined by an absence of significant renal impairment, the HELLP syndrome or thrombocytopenia alone.
Conservative management consisted of advising women to stay in hospital until delivery, with weekly
betamethasone injections up to 32-34 weeks’ gestation, and with frequent fetal and maternal monitoring.
Exclusion criteria: none stated.
59 women were approached and counseled about the study, of which 56 women gave informed written
consent, and allocated to either the vitamin group (n = 27) or placebo (n = 29)
Interventions Women randomised to the vitamin group received twice daily 400 IU vitamin E (800 IU daily total), 500
mg vitamin C (1000 mg daily total) and 100 mg allopurinol (200 mg daily total). Women randomised to
the placebo group received the same number of tablets that were identical to the vitamin C and allopurinol
tablets. Vitamin C placebos were used as placebos for vitamin E because it was not possible to obtain
two separate sets of placebos from the supplier; however, the vitamin E tablets and their placebos were
slightly different. To preserve blinding all medications were placed in dark brown coloured bottles and
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Gulmezoglu 1997 (Continued)
sealed opaque paper bags
Outcomes 1. Delivery within 14 days.
2. Maternal deaths.
3. Serious maternal complications (pulmonary oedema, eclampsia, HELLP syndrome, disseminated in-
travascular coagulation, renal failure).
4. Placental abruption.
5. Prelabour caesarean section.
6. Use of antihypertensives.
7. Stillbirth.
8. Apgar score < 7 at 1 minute and < 7 at 5 minutes.
9. Umbilical artery pH < 7.2.
10. Admission to intensive care unit.
11. Mechanical ventilation.
12. Neonatal death.
13. Perinatal death.
14. Birthweight (median, range).
15. Lipid peroxide and vitamin E levels.
16. Haematological and renal function parameters.
17. Placental lipid peroxide and glutathione levels.
Notes Dosage: 800 IU vitamin E, above RDI.
GA at trial entry: > 20 weeks’ gestation.
Dietary vitamin E intake before trial entry: unclear, no dietary information reported
Type of supplement: vitamin E given in addition to vitamin C and allopurinol
Women’s risk status: women had established early onset severe pre-eclampsia
Intention to treat analyses: all data were reported according to women’s treatment allocation, and were
available for all women for the primary outcome. There were missing data for the outcomes Apgar score
< 7 at 1 minute, Apgar score < 7 at 5 minutes, umbilical artery pH < 7.2, and the lipid peroxide and
vitamin E levels and haematological and renal function parameters
Sample size calculation: a sample size of 54 women had 80% power to detect a halving in the number of
women needing delivery within 14 days, from 80% to 40%
Compliance: compliance in the vitamin group was estimated at 84%, 89%, 93% for the vitamin E,
vitamin C and allopurinol tablets. For the placebo group compliance was 75%, 100% and 86% for the
vitamin E, vitamin C and allopurinol placebo tablets
Location: Johannesburg, South Africa.
Timeframe: unclear.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Rivas 2000
Methods Treatment allocation: unclear, women were “randomly divided into two sub-groups”
Blinding of outcome assessment: “triple blind” stated.
Documentation of exclusion: none stated.
Use of placebo control: placebo control.
Participants 127 women were recruited into the study. Inclusion criteria: women less than 29 weeks’ gestation and with
“high risk for pre-eclampsia”, including any of the following factors: nulliparity, previous pre-eclampsia,
obesity, hypertension, less than 20 years old, diabetes, nephropathy, mean arterial presion above of 85
mmHg, positive roll-over test, black race, family history of hypertension or pre-eclampsia, twin pregnancy
and poor socioeconomic conditions.
Exclusion criteria: unclear, none stated. 127 women were allocated to vitamins C and E, aspirin and fish
oil (n = 63) or placebo (n = 64)
Interventions Women allocated to the treatment group received 400 IU vitamin E per day, 500 mg vitamin C per day,
100 mg aspirin three times a week and 1 g fish oil three times a day.
Women allocated to the placebo group, received placebo “at the same posology and presentation”
Outcomes 1. Pre-eclampsia (not defined).
2. The authors report that “no serious maternal and neonatal side effects of treatment occurred in either
group”, no other details were given
Notes Dosage: daily 400 IU vitamin E, above RDI.
GA at trial entry: unclear, “less than 29 weeks”.
Dietary vitamin E intake before trial entry: unclear, no dietary information reported
Type of supplement: vitamin E in addition to vitamin C, aspirin and fish oil
Women’s risk status: women were at “high risk for pre-eclampsia”
Intention to treat analyses: unclear, no details given.
Sample size calculation: unclear, reported as an abstract only
Compliance: no details given.
Location: Merida, Venezuela.
Timeframe: unclear, no details given.
Published in abstract format only.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
GA: gestational age
HELLP: haemolysis, elevated liver enzymes, low platelets
IQR: interquartile range
IU: international units
PAI-1: plasminogen activator inhibitor-1
PAI-2: plasminogen activatory inhibitor-2
RDI: recommended dietary intake
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anthony 1996 No clinical outcomes reported. Randomised controlled trial or seventy-three women undergoing conservative
management of pre-eclampsia were supplemented with vitamin E (no dose information available). The abstract
reported no differences in any of the clinical outcomes between the treatment groups; however, no other details
were given. There are no further publications and no other information is available (personal communication
with Prof J Anthony, August 2004)
Bolisetty 2002 Not a randomised trial, pilot case control study. Twelve women at risk of preterm birth and between 30 and 36
week’s gestation were given daily 20 mg beta-carotene, 167.8 mg vitamin E and 1000 mg vitamin C or acted
as controls. Biochemical assessments of oxidative stress and maternal plasma concentrations of beta-carotene,
vitamin E and vitamin C were reported
Lietz 2001 Not a randomised trial. Women were supplemented with either red palm oil (a source of vitamin A), sunflower
oil (a source of vitamin E) or acted as control. Allocation to treatment groups was “based on practicality”.
Reported outcomes included measures of plasma and breast milk vitamin A status, maternal haemoglobin and
maternal weight
Moldenhauer 2002 No clinical outcomes reported. Women in this study were participating in a randomised placebo controlled
trial of calcium supplementation, and completed a dietary assessment at 12-21 weeks’ gestation and 29-31
weeks’ gestation. Women were not randomised to vitamin E supplementation. Unclear whether all women
took a standard prenatal multivitamin or just women in the placebo group. Results are presented according to
“teens”, “twins” and “singleton” pregnancies, not according to whether women took the supplement or not.
Outcomes reported included dietary intakes of vitamin C and E (with and without the contribution of the
prenatal vitamin supplement). Published in abstract form only
Pressman 2003 No clinical outcomes reported. Randomised controlled trial supplementing women with daily 500 mg vita-
min C and 400 IU vitamin E from 35 weeks’ gestation. Maternal plasma concentrations and amniotic fluid
concentrations of vitamin C and E reported
Sawhney 2000 No clinical outcomes reported. Randomised controlled trial of sixty women with established pre-eclampsia
allocated to either vitamin E (no dose information given) or control. Reported outcomes were lipid peroxide
and alpha-tocopherol levels and the percentage of women whose pregnancy continued for more than 14 days.
No other information given. Published in abstract format only
IU: international units
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Characteristics of ongoing studies [ordered by study ID]
ACTS
Trial name or title Australian Collaborative Trial of Supplements with vitamin C and vitamin E for the prevention of pre-
eclampsia: a randomised controlled trial
Methods
Participants Inclusion criteria:
nulliparous women with a singleton pregnancy, between 14 + 0 and 21 + 6 weeks’ gestation, with normal
blood pressure, expecting to give birth at the collaborating centre, with no contraindication to vitamin C or
E therapy and giving informed written consent
Exclusion criteria:
women with a multiple pregnancy, life threatening fetal anomaly on ultrasound, known thrombophilia,
chronic renal failure, haemochromatosis or on heparin, warfarin or antihypertensive therapy
Interventions Daily 1000 mg vitamin C and 400 IU vitamin E or placebo.
Outcomes Primary outcomes:
Incidence of:
1. small-for-gestational-age infants.
2. clinical pre-eclampsia.
3. death or serious adverse outcome for the infant.
Starting date December 2001.
Contact information Prof. C Crowther
Ms A Rumbold,
Department of Obstetrics and Gynaecology, The University of Adelaide.
Email: acts@adelaide.edu.au
Notes
DAPIT 2004
Trial name or title The Diabetes and Pre-eclampsia Intervention Trial (DAPIT).
Methods
Participants Inclusion criteria:
Type 1 diabetes preceding pregnancy; age >= 16 years; between 8 and 22 weeks’ gestation; date of last
menstrual period certain and/or ultrasound estimation from6-22weeks of gestational age is available; singleton
pregnancy.
Exclusion criteria:
ingestion of preparations containing vitamin C > 500 mg/day or vitamin E > 200 IU/day; participation in
another study which may interfere with DAPIT; participation in DAPIT during a previous pregnancy, where
DAPIT trial medication was taken within the last 6 months; any notation of drug abuse: cocaine, LSD,
heroin, marijuana, inhaled solvents/gases; warfarin therapy.
Planned sample size: 945 women.
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DAPIT 2004 (Continued)
Interventions Daily 1000 mg vitamin C and 400 IU vitamin E or placebo.
Outcomes Primary outcome:
Incidence of pre-eclampsia.
Secondary outcomes: endothelial activation, birthweight centile
Starting date April 2003.
Contact information Dr David RMcCance, Consultant Physician / Honorary Senior Lecturer, Regional Centre for Endocrinology
and Diabetes, Royal Victoria Hospital, Belfast BT12 6BA.
Email: david.mccance@royalhospitals.n-i.nhs.uk
Notes
Fraser 2002
Trial name or title Bi-national randomised controlled trial of vitamin C and E supplementation to prevent pre-eclampsia
Methods
Participants Two stratum’s of participants:
1. nulliparous women without additional risk factors.
2. nulliparous women with at least one of the risk factors: diabetes, chronic hypertension, obesity, multiple
pregnancy, and for multiparous women, a past history of pre-eclampsia
Interventions Daily 1 g vitamin C and 400 IU vitamin E or placebo.
Outcomes Frequency of pre-eclampsia, gestation hypertension with adverse conditions, intrauterine growth restriction,
preterm birth
Starting date Unclear.
Contact information Prof W Fraser Department of Obstetrics and Gynaecology, Laval University, Quebec, Canada.
Email: william.fraser@ogy.ulaval.ca
Notes
NICHD MFMU Network
Trial name or title Combined Antioxidants and Pre-eclampsia Prediction Studies (CAPPS)
Methods
Participants Gestational age 9 + 0 - 16 + 6 weeks, singleton pregnancy, nulliparous,
BP < 135/85 mmgHg, no antihypertensive medication/diuretics, proteinuria 0 or trace, no vitamin C or E >
amount in prenatal vitamins and with informed consent
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NICHD MFMU Network (Continued)
Interventions Daily dose 1000 mg vitamin C/400 IU vitamin E or placebo until delivery
Outcomes Primary outcomes:
BP > 160/110 mmHg or BP > 140/90 mmHg > 20 weeks and one of:
1. SGOT (AST) > 100 U/L.
2. Platelets < 100,000/mm3.
3. Creatinine > 1.5 mg/dL.
4. Eclampsia.
5. Fetal/neonatal death.
6. SGA < 3rd percentile.
7. Preterm delivery < 32 wks.
Starting date Enrolment: May 2003-April 2005.
Data collect on: May 2003-March 2006.
Closeout/final analysis: April 2006-November 2006.
Contact information Prof JM Roberts, Director, Magee-Women’s Research Institute
Professor and Vice Chair (Research) of Obstetrics, Gynecology and Reproductive Sciences, University of
Pittsburgh.
Email: rsijmr@mwri.magee.edu
Notes
Poston 2002
Trial name or title Vitamins in Pre-eclampsia (VIP).
Methods
Participants Inclusion criteria:
1. primiparous women with no known risk factors between 14 and 21 weeks’ gestation;
2. women at risk of pre-eclampsia (previous pre-eclampsia, essential hypertension, diabetes, SLE with renal
dysfunction, APS, obesity, multiple pregnancy)
Exclusion criteria:
women unable to give informed consent or who have a daily intake of supplements vitamin C > 200 mg,
vitamin E > 50 IU or those taking warfarin
Interventions Daily 1 g vitamin C and 400 IU vitamin E
Outcomes Incidence of pre-eclampsia, birthweight centile (< 5th).
Starting date August 2003.
Contact information Prof L Poston and Prof A Shennan, Maternal and Fetal Research Unit, Department of Women’s Health, 10th
Floor North Wing, St Thomas’ Hospital, Lambeth Palace Road. London SE1 7EH.
Email: lucilla.poston@kcl.ac.uk or
andrew.shennan@kcl.ac.uk
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Poston 2002 (Continued)
Notes
AST: aspartate aminotransferase
APS: antiphospholipid syndrome
BP: blood pressure
IU: international unit
SGA: small for gestational age
SGOT: serum glutamic-oxaloacetic transaminase
SLE: systemic lupus erythematosus
U/L: units/litre
wks: weeks
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D A T A A N D A N A L Y S E S
Comparison 1. Any vitamin E supplementation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Stillbirth 2 339 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.35, 1.71]
2 Neonatal death 1 40 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.64, 39.06]
3 Perinatal death 1 56 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.67, 2.48]
4 Infant death 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Haemolytic anemia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Reticulocytosis 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7 Hyperbilirubinemia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8 Haemoglobin levels 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8.1 Maternal 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8.2 Infant 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Preterm birth (less than 37
weeks’ gestation)
2 383 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.78, 2.15]
10 Clinical pre-eclampsia (fixed-
effect model)
3 510 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.27, 0.71]
11 Clinical pre-eclampsia
(random-effects model)
3 510 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.16, 1.22]
12 Intrauterine growth restriction
(less than third centile or the
most extreme centile reported)
2 383 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.49, 1.04]
12.1 Birthweight < 10th
centile
2 383 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.49, 1.04]
13 Birthweight 1 100 Mean Difference (IV, Fixed, 95% CI) -139.0 [-517.68,
239.68]
14 Prelabour rupture of fetal
membranes
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
14.1 Preterm 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
14.2 Term 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15 Maternal death 1 56 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16 Elective delivery and caesarean
section
1 55 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [0.86, 2.63]
16.1 Prelabour caesarean
section
1 55 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [0.86, 2.63]
17 Bleeding episodes 2 339 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.10, 1.23]
17.1 Placental abruption 2 339 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.10, 1.23]
18 Measures of serious maternal
morbidity
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
18.1 Eclampsia 1 56 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.07, 16.33]
18.2 Renal failure 1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.02, 8.41]
18.3 Disseminated
intravascular coagulation
1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.02, 8.41]
18.4 Pulmonary oedema 1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.05, 5.59]
19 Peripheral neuropathy 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
19.1 Maternal 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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19.2 Infant 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
20 Maternal satisfaction with care 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
21 Gestational age at birth 1 100 Mean Difference (IV, Fixed, 95% CI) -0.40 [-1.87, 1.07]
22 Congenital malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
23 Apgar score less than seven at
five minutes
1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.21, 1.90]
24 Vitamin K deficiency bleeding
or haemorrhagic disease of the
newborn
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
25 Respiratory distress syndrome 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
26 Chronic lung disease 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
27 Periventricular haemorrhage
and periventricular
leukomalacia
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
28 Bacterial sepsis 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
29 Necrotising enterocolitis 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
30 Retinopathy of prematurity 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
31 Bronchopulmonary dysplasia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
32 Disability at childhood follow
up
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
33 Poor childhood growth 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
34 Adverse events related to
vitamin E supplementation
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
35 Side-effects of vitamin E
supplementation
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
35.1 Acne 1 56 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.14, 75.68]
35.2 Transient weakness 1 56 Risk Ratio (M-H, Fixed, 95% CI) 5.36 [0.27, 106.78]
35.3 Skin rash 1 56 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.14, 75.68]
36 Use of health service resources -
maternal
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
37 Use of health service resources -
infant
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
37.1 Admission to intensive
care unit
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.30, 2.29]
37.2 Use of mechanical
ventilation
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.08, 1.46]
Comparison 2. Any vitamin E supplementation (sensitivity analyses by trial quality)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Stillbirth 2 339 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.35, 1.71]
1.1 High quality (allocation
concealment = A, blinding,
< 3% exclusions and use of
placebo)
2 339 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.35, 1.71]
2 Neonatal death 1 40 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.64, 39.06]
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2.1 High quality (allocation
concealment = A, blinding,
< 3% exclusions and use of
placebo)
1 40 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.64, 39.06]
3 Perinatal death 1 56 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.67, 2.48]
3.1 High quality (allocation
concealment = A, blinding,
< 3% exclusions and use of
placebo)
1 56 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.67, 2.48]
4 Preterm birth (< 37 weeks’
gestation)
1 283 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.38, 3.87]
4.1 High quality (allocation
concealment = A, blinding,
< 3% exclusions and use of
placebo)
1 283 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.38, 3.87]
5 Clinical pre-eclampsia 1 283 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.24, 0.91]
5.1 High quality (allocation
concealment = A, blinding,
< 3% exclusions and use of
placebo)
1 283 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.24, 0.91]
6 Intrauterine growth restriction 1 283 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.50, 1.08]
6.1 High quality (allocation
concealment = A, blinding,
< 3% exclusions and use of
placebo)
1 283 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.50, 1.08]
Comparison 3. Any vitamin E supplementation (subgroup analyses based on gestation at entry)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Stillbirth 2 339 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.35, 1.71]
1.1 Less than or equal to 20
week’s gestation
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 Greater than 20 weeks’
gestation
1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.36, 1.93]
1.3 Both prior to and after 20
weeks’ gestation
1 283 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.05, 5.49]
2 Preterm birth 2 383 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.78, 2.15]
2.1 Less than or equal to 20
weeks’ gestation
1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.75, 2.31]
2.2 Greater than 20 weeks’
gestation
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2.3 Both prior to and after 20
weeks’ gestation
1 283 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.38, 3.87]
3 Clinical pre-eclampsia 3 510 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.16, 1.22]
3.1 Less than or equal to 20
weeks’ gestation
1 100 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.40, 2.13]
25Vitamin E supplementation in pregnancy (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3.2 Greater than 20 weeks’
gestation
0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
3.3 Both prior to and after 20
weeks’ gestation
2 410 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.04, 1.46]
4 Intrauterine growth restriction 2 383 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.49, 1.04]
4.1 Less than or equal to 20
week’s gestation
1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.09, 2.41]
4.2 Greater than 20 weeks’
gestation
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.3 Both prior to and after 20
weeks’ gestation
1 283 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.50, 1.08]
WH A T ’ S N E W
Last assessed as up-to-date: 16 December 2004.
Date Event Description
7 May 2010 Amended Search updated. Twenty-three new reports added to Studies awaiting classification
H I S T O R Y
Protocol first published: Issue 1, 2003
Review first published: Issue 2, 2005
Date Event Description
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